{
    "organizations": [],
    "uuid": "253c6000ddf808956483aa956f881e5703a64f27",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-quentis-therapeutics-debuts-with-4/brief-quentis-therapeutics-debuts-with-48-mln-series-a-financing-idUSASB0C7OH",
    "ord_in_thread": 0,
    "title": "BRIEF-Quentis Therapeutics Debuts With $48 Mln Series A Financing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Quentis Therapeutics:\n* QUENTIS THERAPEUTICS DEBUTS WITH $48 MILLION SERIES A FINANCING TO ADVANCE FIRST-IN-CLASS IMMUNOTHERAPIES TARGETING ENDOPLASMIC RETICULUM STRESS RESPONSE PATHWAYS\n* QUENTIS THERAPEUTICS ​- ‍SERIES A FINANCING CO-LED BY VERSANT VENTURES, POLARIS PARTNERS, AFFILIATED LS POLARIS INNOVATION FUND Source text for Eikon:\n ",
    "published": "2018-02-27T20:49:00.000+02:00",
    "crawled": "2018-02-28T12:53:33.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "quentis",
        "therapeutic",
        "quentis",
        "therapeutic",
        "debut",
        "million",
        "series",
        "financing",
        "advance",
        "immunotherapy",
        "targeting",
        "endoplasmic",
        "reticulum",
        "stress",
        "response",
        "pathway",
        "quentis",
        "therapeutic",
        "financing",
        "versant",
        "venture",
        "polaris",
        "partner",
        "affiliated",
        "l",
        "polaris",
        "innovation",
        "fund",
        "source",
        "text",
        "eikon"
    ]
}